2-Amino-3-methylbenzoic acidCAS# 4389-45-1 |
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
| Cas No. | 4389-45-1 | SDF | Download SDF |
| PubChem ID | 78101 | Appearance | Powder |
| Formula | C8H9NO2 | M.Wt | 151 |
| Type of Compound | N/A | Storage | Desiccate at -20°C |
| Solubility | Soluble in Chloroform,Dichloromethane,Ethyl Acetate,DMSO,Acetone,etc. | ||
| Chemical Name | 2-amino-3-methylbenzoic acid | ||
| SMILES | CC1=CC=CC(=C1N)C(=O)O | ||
| Standard InChIKey | WNAJXPYVTFYEST-UHFFFAOYSA-N | ||
| Standard InChI | InChI=1S/C8H9NO2/c1-5-3-2-4-6(7(5)9)8(10)11/h2-4H,9H2,1H3,(H,10,11) | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
2-Amino-3-methylbenzoic acid Dilution Calculator
2-Amino-3-methylbenzoic acid Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 6.6225 mL | 33.1126 mL | 66.2252 mL | 132.4503 mL | 165.5629 mL |
| 5 mM | 1.3245 mL | 6.6225 mL | 13.245 mL | 26.4901 mL | 33.1126 mL |
| 10 mM | 0.6623 mL | 3.3113 mL | 6.6225 mL | 13.245 mL | 16.5563 mL |
| 50 mM | 0.1325 mL | 0.6623 mL | 1.3245 mL | 2.649 mL | 3.3113 mL |
| 100 mM | 0.0662 mL | 0.3311 mL | 0.6623 mL | 1.3245 mL | 1.6556 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- JIP-1 (153-163)
Catalog No.:BCC5777
CAS No.:438567-88-5
- 3(20)-Phytene-1,2-diol
Catalog No.:BCN6589
CAS No.:438536-34-6
- PFK-015
Catalog No.:BCC5280
CAS No.:4382-63-2
- Perakine
Catalog No.:BCN5491
CAS No.:4382-56-3
- Robtin
Catalog No.:BCN5490
CAS No.:4382-34-7
- Dihydrorobinetin
Catalog No.:BCN5489
CAS No.:4382-33-6
- Quercetin 3,3'-dimethyl ether
Catalog No.:BCN7781
CAS No.:4382-17-6
- SMI-4a
Catalog No.:BCC2233
CAS No.:438190-29-5
- 4-(4-Aminophenyl)morpholin-3-one
Catalog No.:BCC8650
CAS No.:438056-69-0
- H-Thr(tBu)-OH
Catalog No.:BCC3106
CAS No.:4378-13-6
- Salinosporamide A (NPI-0052, Marizomib)
Catalog No.:BCC2094
CAS No.:437742-34-2
- Crategolic acid
Catalog No.:BCN5487
CAS No.:4373-41-5
- Gentianine
Catalog No.:BCN5492
CAS No.:439-89-4
- O-2093
Catalog No.:BCC7070
CAS No.:439080-01-0
- Afatinib
Catalog No.:BCC3656
CAS No.:439081-18-2
- Bay 60-7550
Catalog No.:BCC1405
CAS No.:439083-90-6
- Lasmiditan
Catalog No.:BCC4077
CAS No.:439239-90-4
- GW 627368
Catalog No.:BCC7961
CAS No.:439288-66-1
- ITK inhibitor
Catalog No.:BCC1662
CAS No.:439574-61-5
- BMS-509744
Catalog No.:BCC1424
CAS No.:439575-02-7
- NPY 5RA972
Catalog No.:BCC7747
CAS No.:439861-56-0
- Gnetifolin M
Catalog No.:BCN3394
CAS No.:439900-84-2
- Isoscabertopin
Catalog No.:BCN4634
CAS No.:439923-16-7
- Trifluoperazine 2HCl
Catalog No.:BCC4384
CAS No.:440-17-5
The in vivo oxidative metabolism of 2,4- and 2,6-dimethylaniline in the dog and rat.[Pubmed:2749743]
Toxicology. 1989 Jul 3;57(1):45-58.
The xylidine 2,4-dimethylaniline (2,4-DMA) produces hepatic cholangiofibrosis, bile duct proliferation, and foci of cellular hyperplasia and degeneration in the rat. The same compound is relatively innocuous in the dog. 2,6-Dimethylaniline (2,6-DMA) does not produce hepatic lesions in the rat, except at high doses but is a potent inducer of fatty degeneration in the dog. The purpose of the present study was to examine pathways of in vivo metabolism of both isomers in the rat and dog. The major urinary metabolite of 2,4-DMA in the rat was N-acetyl-4-amino-3-methylbenzoic acid (AAMBA) while in the dog it was 6-hydroxy-2,4-dimethylaniline (6-HDMA). The dog also produced a smaller amount of unacetylated 4-amino-3-methylbenzoic acid (4-AMBA) and its glycine conjugate. 2,6-DMA was metabolized principally to 4-hydroxy-2,6-dimethylaniline (4-HDMA) in both species, but the dog also produced significant quantities of 2-Amino-3-methylbenzoic acid (2-AMBA), along with trace amounts of the glycine conjugate of the latter and 2,6-dimethylnitrosobenzene. Trace levels of an unknown postulated to be 3,5-dimethyl-4-imino-quinone were also found in urine of dogs. In rats, repeated administration of either xylidine for 10 days failed to increase the appearance of metabolites, but 3-methylcholanthrene (3-MC) did increase the urinary concentration of AAMBA in 2,4-DMA dosed rats. The divergent pathways of metabolism in the 2 species could be responsible for species specific pathologies produced by these 2 xylidines.
Lidocaine metabolism by rabbit-liver homogenate and detection of a new metabolite.[Pubmed:3751122]
Xenobiotica. 1986 Jul;16(7):681-90.
Metabolism of lidocaine in rabbit liver 9000 g supernatant fraction was examined. A capillary g.l.c. assay was developed to separate seven known metabolites of lidocaine, and all seven metabolites were identified in extracts of incubations of lidocaine with rabbit-liver fractions. These metabolites were monoethylglycinexylidide(I), glycinexylidide(II), 3-hydroxymonoethylglycinexylidide(III), 3-hydroxylidocaine(IV), 4-hydroxylidocaine(V), xylidine(VI) and 4-hydroxyxylidine(VII). A new metabolite, 2-Amino-3-methylbenzoic acid(VIII), was identified in extracts of incubations of lidocaine with rabbit-liver fractions, by comparison of the mass-spectral fragmentation patterns and g.l.c. retention time with those of the authentic compound. The formation of VIII is dependent on protein, NADPH, time, O2, and the presence of soluble enzymes. Quantitative analysis of metabolites I-VIII after a two hour incubation accounts for 89% of the metabolized lidocaine.
